| 罗劲松,杨小平,马春花,张小玲,姚金梅,马莉雅.脾氨肽联合普米克令舒对小儿支气管哮喘的临床疗效及对CD4+, CD8+, IgE水平的影响[J].,2017,17(26):5058-5061 |
| 脾氨肽联合普米克令舒对小儿支气管哮喘的临床疗效及对CD4+, CD8+, IgE水平的影响 |
| Clinical Effect of Splenic Aminopeptide Combined with Pulmicort on Bronchial Asthma and Serum Levels of CD4+, CD8+ and IgE |
| 投稿时间：2017-03-12 修订日期：2017-03-30 |
| DOI：10.13241/j.cnki.pmb.2017.26.012 |
| 中文关键词: 脾氨肽 普米克令舒 支气管哮喘 免疫功能 |
| 英文关键词: Spleen ammonia peptide Pulmicort Bronchial asthma Immune function |
| 基金项目:湖北省自然科学基金项目(2007ABA080) |
|
| 摘要点击次数: 141 |
| 全文下载次数: 72 |
| 中文摘要: |
| 摘要 目的：分析脾氨肽联合普米克治疗小儿支气管哮喘的临床疗效及对患儿CD4+、CD8+、血清IgE水平的影响。方法：选取我院2015年6月～2016年10月收治的支气管哮喘急性发作患儿88例，采用随机数字法将其分为对照组和观察组，每组各44例。所有患儿进行止咳化痰治疗，对照组患儿在此基础上采用雾化吸入普米克令舒混悬液，观察组患儿在对照组用药基础上加用脾氨肽口服冻干粉。比较两组患儿的临床疗效、症状消失时间、肺功能变化情况、住院时间及治疗前后CD4+、CD8+、CD4+/CD8+及血清IgE水平的变化。结果：观察组的治疗总有效率显著高于对照组(P<0.01)。治疗后，观察组的咳嗽、胸部哮鸣音、喘憋消失时间及住院时间均明显短于对照组(P<0.01)，FVC、FEV1及FEV/FVC、CD4+、CD4+/CD8+水平均显著高于对照组(P<0.01)，而血清IgE浓度明显低于对照组(P<0.01)。两组不良反应发生率及CD8+水平比较差异无统计学意义(P>0.05)。结论：脾氨肽联合普米克令舒可显著提高小儿支气管哮喘的临床疗效，迅速改善患儿的临床症状及免疫功能，且安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical effect of splenic aminopeptide combined with pulmicort on the bronchial asthma in children and its effect on the CD4+, CD8+ and serum IgE concentrations. Methods: 88 cases of patients with acute exacerbation of bronchial asthma in our hospital from June 2015 to October 2016 were selected and randomly divided into the control group and the observation group, 44 cases in each group. All the children were treated with cough and phlegm. In addition, the control group was given inhalation of Pulmicort suspension, the observation group of children was treated by spleen ammonia peptide oral freeze-dried powder on the basis of control group. The clinical efficacy, disappearance time of clinical symptoms, changes of lung function, hospitalization time and levels of CD4+, CD8+, CD4+/CD8+, Serum IgE concentration before and after treatment were compared between two groups. Results: The total effective rate of treatment group was significantly higher than that of the control group (P<0.01). After treatment, the disappearance time of cough, chest wheezing, wheezing and hospitalization time of observation group were significantly shorter than those of the control group (P<0.01), the FVC, FEV1 and FEV1/FVC, CD4+, CD4+/CD8+ levels after treatment were significantly higher than those in the control group (P<0.01), and the serum IgE concentration was lower than that of the control group(P<0.01). There was no significant difference in the incidence of adverse reactions and CD8+ between the two groups(P>0.05). Conclusion: Splenic aminopeptide combined with Pulmicort could enhance the clinical efficacy of children with bronchial asthma, which could quickly improve the clinical symptoms and immune function with high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
